Key Highlights

  • PAVmed shares were up 9.95% to USD 2.10 in pre-market trading on November 3, 2026.
  • No new announcement explaining the move was identified; the latest release, dated October 30, 2026, scheduled a Q3 call.
  • The Q3 2026 Business update call is set for November 13, 2026 at 8:30 AM ET.
  • Cash was USD 3.8 million at June 30, 2026, up from USD 1.5 million at December 31, 2025.
  • Second quarter 2026 Revenue was USD 33 thousand, with a net loss attributable to common stockholders of about USD 5.5 million.

What Moved PAVmed Stock in Pre-Market Trading (up USD 0.1900, 9.95%)?

PAVmed Inc. (NASDAQ:PAVM) was up 9.95% to USD 2.10 in pre-market trading on November 3, 2026, measured against the Monday, November 2 close. No company announcement explaining the jump was identified for November 2 or November 3. The latest item is a press release dated October 30, 2026, which set the date for the third quarter update. The move therefore looks more like momentum or sector-driven trading than a reaction to news.

What Did the Latest Company Release Say?

According to the company press release dated October 30, 2026, PAVmed will hold its Third Quarter 2026 business update call on Friday, November 13, 2026, at 8:30 AM ET. Chairman and Chief Executive Officer Lishan Aklog, M.D., will give the update, and President and Chief Financial Officer Dennis McGrath will discuss financial results.

The notice contained no financial results.

What Does PAVmed Do and How Did Its Latest Quarter Look?

PAVmed describes itself as a diversified, commercial-stage medical technology company in devices, diagnostics and digital health. Its subsidiaries include Lucid Diagnostics (NASDAQ:LUCD), which markets the EsoGuard Esophageal DNA Test for early detection of esophageal precancer, and Veris Health, which offers remote monitoring for personalized cancer care.

In its second quarter 2026 report dated August 14, 2026, PAVmed posted revenue of USD 33 thousand, against USD 6 thousand a year earlier. Operating expenses were about USD 7.1 million, and the net loss attributable to common stockholders was about USD 5.5 million, or USD 0.87 per diluted share. Lucid recognized USD 1.5 million of EsoGuard revenue and processed 2,770 tests. The Veris implantable monitor is targeting an early 2027 FDA 510(k) submission, the company said.

What Are the Balance Sheet and Penny Stock Risks?

Cash stood at USD 3.8 million at June 30, 2026, against six-month operating expenses of USD 15.1 million, so the company depends on raising additional funding, a risk it flags in its filings. Calculated from those figures, cash covers roughly one quarter of spending at the first-half pace. Penny stocks like this one are prone to sharp volatility, thin Liquidity and potential dilution if new Equity is issued.

What Should Investors Watch Next?

The key date is the November 13, 2026 call, where management is expected to discuss third quarter results, cash, funding plans and EsoGuard testing and coverage. Investors may also look for updates on the Veris monitor submission and the PortIO FDA meeting request planned for the fourth quarter of 2026.